Mosqitter is trying to turn a hardware business into a surveillance network for mosquito-borne disease. The Pennsylvania-based startup sells chemical-free traps that mimic human heat, scent and breathing cues. It has now deployed more than 5,000 devices across five continents, up from just over 250 in 2022, according to management.
Its newer Febris system uses sensors and artificial intelligence to identify mosquito species during capture, combine that information with weather data and map population changes. The value proposition is not simply killing insects. Governments, public-health agencies and researchers could use the data to identify rising risk earlier and target interventions more precisely.
The public-health need is clear. World Health Organization data cited by TechCrunch showed reported dengue cases rising from 6.5 million in 2023 to a record 14.6 million in 2024. Climate and travel are expanding the range of disease-carrying mosquitoes, but the presence of a species does not prove that local insects carry a pathogen or that an outbreak will follow.
A subscription business with scientific obligations
Mosqitter’s Mini trap sells for $199 and its professional Grand system for $1,999. Hardware sales generate immediate revenue, while Febris is intended to add recurring fees for monitoring, dashboards and analytics. The company expects more than $1 million of total revenue in 2026 and projects that the data business could produce over $3.5 million in 2027 based on contracts it is bidding for. Those are management forecasts, not signed-revenue disclosures.
The system’s commercial quality will depend on species-identification accuracy, uptime, maintenance cost and the usefulness of alerts to health officials. False positives could waste public resources, while missed detections could create false reassurance. Customers will also need transparent methods for combining trap observations with weather and disease data.
Mosqitter has raised $1.9 million and is seeking another $5 million in two tranches. That is modest capital for manufacturing hardware, supporting a global fleet and validating health analytics.
The opportunity is attractive because recurring data can carry better economics than one-time devices. The evidence needed next is equally concrete: independently tested classification accuracy, renewal rates, signed monitoring contracts and proof that the alerts improve decisions rather than merely produce more data.